<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01333631</url>
  </required_header>
  <id_info>
    <org_study_id>SOR513511CTIL</org_study_id>
    <nct_id>NCT01333631</nct_id>
  </id_info>
  <brief_title>Valproic Acid With Chemoradiotherapy for Pancreatic Cancer</brief_title>
  <official_title>Valproic Acid in Combination With Concurrent Chemoradiotherapy Using Gemcitabine for Unresectable Locally Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Soroka University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Soroka University Medical Center</source>
  <brief_summary>
    <textblock>
      This is non-randomized phase 2 study to evaluate toxicity and efficacy of valproic acid (VA)&#xD;
      with concurrent chemoradiotherapy (CCRT) containing weekly gemcitabine in patients with&#xD;
      unresectable locally advanced pancreatic cancer (ULAPC). All patients will be planned for&#xD;
      three-dimensional conformal radiotherapy (3-DCRT). A total dose of 54 Gy will be delivered&#xD;
      using 2 Gy daily fractions given over 5 days a week.Intravenous (i.v.) chemotherapy (ChT)&#xD;
      with gemcitabine 300 mg/m2 will be started at the first day of 3-DCRT.Total 5-6 weekly doses&#xD;
      of i.v. ChT will be planned.VA will be administered orally in daily dose of 800 mg. Treatment&#xD;
      with VA will be commenced at the first day and will be terminated at last day of RT.The&#xD;
      patients will be followed till disease progression or death.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of the patients with side effects</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of the patients survived</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Valporoic acid + chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproic acid</intervention_name>
    <description>Valproic acid given concurrent with chemoradiotherapy for patients with pancreatic cancer</description>
    <arm_group_label>Valporoic acid + chemoradiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; 18 years.&#xD;
&#xD;
          2. Newly-diagnosed, histologically/cytologically or CA 19.9 confirmed ULAPC&#xD;
&#xD;
          3. KPS &gt; 60&#xD;
&#xD;
          4. No previous RT to abdomen&#xD;
&#xD;
          5. No serious comorbid condition Version 1, December 1, 2010&#xD;
&#xD;
          6. No treatment with biological response modifiers or cytotoxic agents within four weeks&#xD;
             prior to study entry, apart from induction chemotherapy with gemcitabine&#xD;
&#xD;
          7. No participation in clinical trial using any investigational drug or device within&#xD;
             four weeks prior to study entry&#xD;
&#xD;
          8. No serious complication of malignant condition&#xD;
&#xD;
          9. No previous or concurrent malignancy at other sites except cone biopsied in situ&#xD;
             carcinoma of the uterine cervix and adequately treated basal cell or squamous cell&#xD;
             carcinoma of the skin&#xD;
&#xD;
         10. Adequate organ function as evidenced by the following peripheral blood counts or serum&#xD;
             chemistries at study entry:&#xD;
&#xD;
               -  Hemoglobin &gt; 9.0 Gm/dL&#xD;
&#xD;
               -  WBC count &gt; 4.0x109/L&#xD;
&#xD;
               -  Neutrophile count &gt; 1.5 cells x 109/L,&#xD;
&#xD;
               -  Platelet count &gt; 100 x 109/L,&#xD;
&#xD;
               -  Creatinine &lt; 1.5 mg/dL&#xD;
&#xD;
               -  Total bilirubin &lt; upper limit of normal (ULN)&#xD;
&#xD;
               -  AST/SGOT &lt; ULN&#xD;
&#xD;
               -  Calcium &lt; ULN&#xD;
&#xD;
         11. Ability to sign informed consent&#xD;
&#xD;
         12. Ability to attend follow-up visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Operable disease&#xD;
&#xD;
          2. Distant metastases&#xD;
&#xD;
          3. KPS &lt; 60&#xD;
&#xD;
          4. Previous RT to abdomen&#xD;
&#xD;
          5. Treatment with biological response modifiers or cytotoxic agents other then induction&#xD;
             gemcitabine within four weeks prior to study entry&#xD;
&#xD;
          6. Participation in clinical trial using any investigational drug or device within four&#xD;
             weeks prior to study entry&#xD;
&#xD;
          7. Major surgical procedure within two weeks prior to study entry&#xD;
&#xD;
          8. Serious comorbid condition, inclusive but not limited to myocardial infarction within&#xD;
             previous six months, uncontrolled cardiac arrhythmias, uncontrolled angina pectoris,&#xD;
             active infection including acute hepatitis&#xD;
&#xD;
          9. Serious complication of malignant condition&#xD;
&#xD;
         10. Previous or concurrent malignancy&#xD;
&#xD;
         11. Inadequate organ function as evidenced by the following peripheral blood counts or&#xD;
             serum chemistries at study entry:&#xD;
&#xD;
               -  Hemoglobin &lt; 9.0 Gm/dL&#xD;
&#xD;
               -  WBC count &lt; 4.0x109/L&#xD;
&#xD;
               -  Neutrophile count &lt; 1.5 cells x 109/L,&#xD;
&#xD;
               -  Platelet count &lt; 100 x 109/L,&#xD;
&#xD;
               -  Creatinine &gt; 1.5 mg/dL&#xD;
&#xD;
               -  Total bilirubin &gt; ULN (upper limit of normal)&#xD;
&#xD;
               -  AST/SGOT &gt; ULN&#xD;
&#xD;
               -  Calcium &gt; ULN&#xD;
&#xD;
         12. Inability to sign informed consent&#xD;
&#xD;
         13. Psychological, familial, sociological or geographical conditions which do permit&#xD;
             regular medical follow-up and compliance with the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Konstantin Lavrenkov, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Soroka University Medical Center</affiliation>
  </overall_official>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>March 27, 2011</study_first_submitted>
  <study_first_submitted_qc>April 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2011</study_first_posted>
  <last_update_submitted>April 10, 2011</last_update_submitted>
  <last_update_submitted_qc>April 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Konstantin lavrenkov</name_title>
    <organization>Soroka University Medical Center</organization>
  </responsible_party>
  <keyword>Locally advanced unresectable pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

